Clearbridge Investments, LLC Pro Qr Therapeutics N.V. Transaction History

Clearbridge Investments, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 12, 2020	SELL	$4.79 - $6.3 $4,679 - $6,155	-977 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$5.25 - $9.9 $168 - $316	-32 Reduced 3.17%	977 $5,000
Q3 2019 Nov 14, 2019	SELL	$5.76 - $9.44 $2.82 Million - $4.62 Million	-489,798 Reduced 99.79%	1,009 $6,000
Q2 2019 Aug 14, 2019	SELL	$9.1 - $15.55 $40,222 - $68,731	-4,420 Reduced 0.89%	490,807 $0
Q1 2019 May 15, 2019	BUY	$12.5 - $18.48 $36,737 - $54,312	2,939 Added 0.6%	495,227 $6.87 Million
Q4 2018 Feb 14, 2019	SELL	$15.25 - $22.4 $7,152 - $10,505	-469 Reduced 0.1%	492,288 $7.77 Million
Q3 2018 Nov 14, 2018	BUY	$6.45 - $21.6 $1,225 - $4,104	190 Added 0.04%	492,757 $9.54 Million
Q2 2018 Aug 14, 2018	SELL	$2.95 - $7.45 $19,782 - $49,959	-6,706 Reduced 1.34%	492,567 $3.6 Million
Q1 2018 May 15, 2018	BUY	$2.9 - $3.5 $232 - $280	80 Added 0.02%	499,273 $1.54 Million
Q4 2017 Feb 14, 2018	BUY	$2.8 - $4.8 $378 - $648	135 Added 0.03%	499,193 $1.61 Million
Q3 2017 Nov 14, 2017	SELL	$4.35 - $6.45 $5,315 - $7,881	-1,222 Reduced 0.24%	499,058 $2.42 Million
Q2 2017 Aug 14, 2017	BUY	N/A	500,280	500,280 $2.6 Million

17.4M

37.7K

21.3K

Ticker PRQR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,362,096
Market Cap $248M
Description
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...

Get notified when there are updates to the investment portfolio of Clearbridge Investments, LLC, based on Form 13F filings with the SEC.

Stay updated on Clearbridge Investments, LLC with notifications on news.